CTNNB1 comutations are associated with lower PD-L1 expression and TP53-wt status, correlating with improved outcomes in patients with EGFR-mutant NSCLC undergoing osimertinib therapy. This evidence concerns the gene CTNNB1 and non-small cell lung carcinoma.